Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL452322 | 0.77 | CA12 (0.36) | CA12CA1CA2CA7CA13 | |
| SCHEMBL452323 | 0.77 | CA12 (0.36) | CA12CA1CA2CA7CA13 | |
| SCHEMBL441143 | 0.72 | DPP4 (0.49) | — | |
| SCHEMBL452978 | 0.72 | DPP4 (0.49) | — | |
| SCHEMBL5682058 | 0.71 | LMNA (0.42) | ALDH1A1 | |
| SCHEMBL13173829 | 0.71 | DPP4 (0.38) | ALDH1A1CA12CA1CA2CA7 | |
| SCHEMBL28572268 | 0.70 | TRPA1 (0.44) | CA12CA1CA2CA7 | |
| SCHEMBL29109558 | 0.69 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL14733116 | 0.69 | RECQL (0.39) | ALDH1A1 | |
| SCHEMBL16935364 | 0.69 | CES2 (0.39) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273055-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2016-03-01 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | CHEMBRIDGE COPRPORATION | 2015-02-05 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822500-B2 | Tyrosine kinase inhibitors | CHEMBRIDGE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | GREGOR VLAD EDWARD (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038536-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | ALDH1A1 1243/4885CA12 3984/4885CA1 4329/4885 |
| US-20120065233-A1 | TYROSINE KINASE INHIBITORS | ALK, ROS1, ABL1 | ALDH1A1 1243/4885CA12 3984/4885CA1 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.